National Center for Clinical Laboratories, Beijing Hospital, National Center of Gerontology, Beijing Engineering Research Center of Laboratory Medicine, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, P. R. China.
National Center for Clinical Laboratories, Beijing Hospital, National Center of Gerontology, Beijing Engineering Research Center of Laboratory Medicine, Beijing, P. R. China.
Ann Lab Med. 2021 Jan;41(1):68-76. doi: 10.3343/alm.2021.41.1.68. Epub 2020 Aug 25.
Using commutable external quality assessment (EQA) materials is important for monitoring successful harmonization efforts. We assessed the commutability of four human serum pool (HSP) preparations to identify candidate EQA materials for alanine aminotransferase (ALT) and aspartate aminotransferase (AST) activity measurement.
One set each of 85 clinical samples (CSs) was collected for ALT and AST activity measurement. The 15 candidate EQA materials included four types of HSP preparations (A to D): materials A, C, and D contained human original recombinant (HOR) aminotransferases; materials B was mixed leftover samples. The CSs and 15 candidate EQA materials were analyzed using seven routine assays, and the ln-transformed results were analyzed in 21 assay pairs. Commutability was assessed using Deming regression, with a 95% prediction interval (CLSI approach) and the difference in bias with an error component model (International Federation of Clinical Chemistry and Laboratory Medicine [IFCC] approach).
For ALT, all materials were commutable for 14-21 assay pairs according to the CLSI and IFCC approaches. For AST, B01-03 showed commutability for 14-21 assay pairs, and C01-03 and D01-03 showed commutability for no less than 10 assay pairs according to the two approaches. A01-06 were commutable for 9-16 assay pairs according to the CLSI approach, but for 6-9 assay pairs according to the IFCC approach.
Mixed leftover samples showed desirable commutability characteristics as candidate EQA materials for routine aminotransferase activity measurements. Human serum bases supplemented with HOR were commutable for most routine ALT activity measurements.
使用可互换的外部质量评估(EQA)材料对于监测成功的协调工作非常重要。我们评估了四种人血清池(HSP)制剂的可互换性,以确定丙氨酸氨基转移酶(ALT)和天冬氨酸氨基转移酶(AST)活性测量的候选 EQA 材料。
收集了 85 份临床样本(CS)用于 ALT 和 AST 活性测量。15 种候选 EQA 材料包括四种 HSP 制剂(A 至 D):材料 A、C 和 D 含有人类原始重组(HOR)氨基转移酶;材料 B 是混合的剩余样本。使用七种常规测定法分析 CS 和 15 种候选 EQA 材料,ln 转换结果在 21 对测定法中进行分析。使用 Deming 回归评估可互换性,采用 95%预测区间(CLSI 方法)和误差分量模型的偏差差异(国际临床化学和实验室医学联合会 [IFCC]方法)。
对于 ALT,根据 CLSI 和 IFCC 方法,所有材料对于 14-21 对测定法都是可互换的。对于 AST,B01-03 在 14-21 对测定法中显示出可互换性,而 C01-03 和 D01-03 根据这两种方法,对于不少于 10 对测定法显示出可互换性。A01-06 根据 CLSI 方法对于 9-16 对测定法是可互换的,但根据 IFCC 方法对于 6-9 对测定法是可互换的。
混合剩余样本作为常规氨基转移酶活性测量的候选 EQA 材料具有理想的可互换性特征。用人血清基质补充 HOR 对于大多数常规 ALT 活性测量是可互换的。